Compare WHG & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | STXS |
|---|---|---|
| Founded | 1983 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 177.0M |
| IPO Year | 2002 | 2004 |
| Metric | WHG | STXS |
|---|---|---|
| Price | $16.03 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.2K | ★ 368.6K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ 203.85 | 16.67 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $97,762,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | $34.08 |
| Revenue Next Year | N/A | $35.18 |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.51 | $1.58 |
| 52 Week High | $18.99 | $3.59 |
| Indicator | WHG | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 49.51 |
| Support Level | $15.17 | $1.74 |
| Resistance Level | $17.27 | $1.95 |
| Average True Range (ATR) | 0.77 | 0.09 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 65.78 | 63.16 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.